Stock Groups

Krystal Biotech Shares More Than Double After Positive VYJUVEK Trial Results -Breaking

by Mike Robinson

[ad_1]

© Reuters.

Sam Boughedda

Investing.com — Stocks in gene therapy company Krystal Biotech Inc (NASDAQ) surged 117% Monday following the release of positive results from its clinical trial for a treatment of rare skin diseases.

VYJUVEKTM is currently being evaluated as a treatment for Dystrophic Epidermolysis Bullosa, a severe, rare skin condition. GEM-3 achieved its primary goal of complete healing of wounds at six-month intervals, and it met its secondary objective of healing of all wounds at three-month intervals.

Krystal Biotech shares reached a record high of $102.99 according to the latest.

Suma Krishnan, the founder and CEO of Dystrophic Epidermolysis Bullosa, said that this disease is often referred to “the most terrible disease you have ever heard about” because of its devastating effects on patients. 

Krishnan stated, “We are happy to share positive results from the pivotal GEM-3 VYJUVEKTM trial which demonstrated that VYJUVEKTM topical gene treatment led to durable wound repair in dystrophic EB injuries.”

The drug was easily tolerated. Reports of discontinuations or serious adverse reactions were not made.

Investors were informed by the company that the FDA will receive the Biologics License Application (BLA), and it plans to file a European marketing authorization application shortly following the BLA.

Disclaimer: Fusion MediaThis website does not provide accurate and current data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.

[ad_2]